AVH 0.40% $2.46 avita medical inc.

The weak EPS won’t be praised by investors imo. Recell Go won’t...

  1. 1,419 Posts.
    lightbulb Created with Sketch. 324
    The weak EPS won’t be praised by investors imo. Recell Go won’t be a catalyst until it gets that FDA stamp of approval. New data for FDA doesn’t ensure victory; approval does. But the company still needs to execute to obtain profitability by some time in 2025. —Still paying back a high SOFR-rate loan in the meantime.
 
watchlist Created with Sketch. Add AVH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.